Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice.
Shimose S, Saeki I, Tomonari T, Ito T, Tani J, Takeuchi Y, Yoshioka N, Naito T, Takeuchi M, Kakizaki S, Hatanaka T, Sasaki K, Yasunaka T, Sakata M, Iwamoto H, Itano S, Shirono T, Tanabe N, Yamamoto T, Naganuma A, Nishina S, Otsuka M, Kawashima H, Takayama T, Takami T, Kawaguchi T. Shimose S, et al. Among authors: kawashima h. Oncol Lett. 2024 Jun 25;28(2):397. doi: 10.3892/ol.2024.14530. eCollection 2024 Aug. Oncol Lett. 2024. PMID: 38979550 Free PMC article.
Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer.
Ishikawa T, Kawashima H, Ohno E, Matsubara H, Sasaki Y, Achiwa K, Kanamori A, Sumi H, Hirai T, Nonogaki K, Tsuzuki T, Kuroiwa M, Hattori M, Maruta S, Hiramatsu T, Ando M, Hashimoto S, Hirooka Y. Ishikawa T, et al. Among authors: kawashima h. Oncology. 2019;96(1):1-7. doi: 10.1159/000492388. Epub 2018 Oct 26. Oncology. 2019. PMID: 30368509 Clinical Trial.
Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies.
Ito T, Ishigami M, Yamamoto T, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Kawashima H, Yasuda S, Toyoda H, Yokota K, Hase T, Nishio N, Maeda O, Kato M, Hashimoto N, Hibi H, Kodera Y, Sone M, Ando Y, Akiyama M, Shimoyama Y, Fujishiro M. Ito T, et al. Among authors: kawashima h. Hepatol Int. 2021 Oct;15(5):1278-1287. doi: 10.1007/s12072-021-10238-y. Epub 2021 Aug 9. Hepatol Int. 2021. PMID: 34373964
Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Yamamoto T, Ito T, Hase T, Ishigami M, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Shibata H, Hatta T, Yogo N, Yasuda S, Toyoda H, Abe T, Kawashima H, Hashimoto N, Fujishiro M. Yamamoto T, et al. Among authors: kawashima h. Cancer Invest. 2022 Feb;40(2):189-198. doi: 10.1080/07357907.2021.1994586. Epub 2021 Nov 29. Cancer Invest. 2022. PMID: 34658277
A case of antiprogrammed death-ligand 1 antibody-induced multisystem immune-related adverse events with pancreatitis and steroid-resistant sclerosing cholangitis.
Yamamoto T, Ito T, Mizuno K, Shinya Y, Yamamoto K, Imai N, Ishizu Y, Honda T, Kawashima H, Matsui T, Hase T, Hashimoto N, Ishigami M. Yamamoto T, et al. Among authors: kawashima h. J Dig Dis. 2022 Jul;23(7):404-409. doi: 10.1111/1751-2980.13122. J Dig Dis. 2022. PMID: 35962644 No abstract available.
2,128 results